Is it worth using acemetacin? Multidisciplinary at-a-glance Review article
Article Sidebar
Published:
Mar 31, 2018
Keywords:
pain treatment, NSAID, acemetacin, pain
Main Article Content
Abstract
Nonsteroidal anti-inflammatory drugs are commonly used in acute and chronic pain treatment. According to experts’ recommendations, they are first-line drugs in many musculoskeletal disorders and treatment should be individualized. The main limitation of NSAIDs use is gastrointestinal, cardiovascular and platelet safety. Acemetacin, due to its interesting pharmacological properties, can be safely and effectively used in some patients with chronic and acute pain.
Article Details
How to Cite
Kocot-Kępska, M., Kierzkiewicz, M., & Białoszewski, D. (2018). Is it worth using acemetacin? Multidisciplinary at-a-glance. Medycyna Faktow (J EBM), 11(1(38), 59-62. https://doi.org/10.24292/01.MF.0118.9
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Reguła J., Wocial T., Kraszewska E., Butruk E.: Stosowanie niesteroidowych leków przeciwzapalnych w Polsce – badanie ankietowe u 38 tysięcy chorych. Gastroenterologia Kliniczna 2011; 3(2): 72-78.
2. Wisłowska M.: Przewlekłe stosowanie NLPZ – zagrożenia, potencjalne powikłania. Medycyna Rodzinna 2004; 1: 22-26.
3. Li D.M., Lu W.L., Wang X.Q. et al.: Pharmacokinetics of Indomethacin, a Metabolite of Acemetacin, Following a Single dose and Multiple doses Administered as Acemetacin Sustained-Release Tablets in Healthy Male Volunteers. Journal of Health Science 2005; 51(3): 308-316.
4. Lasch H.G., Matis P.: Acemetacin and Diclofenac Therapy in Patients with Degenerative Joint Disease. Die Medizinische Welt 1986; 37: 1073-1076.
5. Laws D.: Double blind parallel group investigation in general practice of the efficacy and tolerability of acemetacin, in comparison with diclofenac, in patients suffering with acute low back pain. British Journal of Clinical Research 1994; 5: 55-64.
6. Chavez-Pina A.E., Vong L., McKnight W. et al.: Lack of effects of acemetacin on signalling pathways for leukocyte adherence may explain its gastrointestinal safety. British Journal of Pharmacology 2008; 155: 857-864.
7. Ridell J., Silke B., Jeffers L. et al.: Effect of acemetacin on the anticoagulant action of warfarin in healthy volunteers. Focus on Acemetacin, Congress of Rheumatology, Barcelona 1993: 23-27.
8. Uncu H.: A comparison of low-molecular-weight heparin and combined therapy of low-molecular-weight heparin with an anti-inflamatory agent in the treatment of superficial wein thrombosis. Phlebology 2009; 24: 56-60.
2. Wisłowska M.: Przewlekłe stosowanie NLPZ – zagrożenia, potencjalne powikłania. Medycyna Rodzinna 2004; 1: 22-26.
3. Li D.M., Lu W.L., Wang X.Q. et al.: Pharmacokinetics of Indomethacin, a Metabolite of Acemetacin, Following a Single dose and Multiple doses Administered as Acemetacin Sustained-Release Tablets in Healthy Male Volunteers. Journal of Health Science 2005; 51(3): 308-316.
4. Lasch H.G., Matis P.: Acemetacin and Diclofenac Therapy in Patients with Degenerative Joint Disease. Die Medizinische Welt 1986; 37: 1073-1076.
5. Laws D.: Double blind parallel group investigation in general practice of the efficacy and tolerability of acemetacin, in comparison with diclofenac, in patients suffering with acute low back pain. British Journal of Clinical Research 1994; 5: 55-64.
6. Chavez-Pina A.E., Vong L., McKnight W. et al.: Lack of effects of acemetacin on signalling pathways for leukocyte adherence may explain its gastrointestinal safety. British Journal of Pharmacology 2008; 155: 857-864.
7. Ridell J., Silke B., Jeffers L. et al.: Effect of acemetacin on the anticoagulant action of warfarin in healthy volunteers. Focus on Acemetacin, Congress of Rheumatology, Barcelona 1993: 23-27.
8. Uncu H.: A comparison of low-molecular-weight heparin and combined therapy of low-molecular-weight heparin with an anti-inflamatory agent in the treatment of superficial wein thrombosis. Phlebology 2009; 24: 56-60.